Copyright
©The Author(s) 2020.
World J Clin Cases. Dec 26, 2020; 8(24): 6264-6273
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6264
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6264
Table 2 Number of patients with hepatitis B virus DNA expression and frequency of hepatitis B virus DNA expression by primary disease in hepatitis B core antibody-positive patients
| Primary disease | n (%) |
| Liver cancer | 9/87 (10.3%) |
| Pancreatobiliary cancer | 6/62 (9.6%) |
| Esophageal cancer | 5/72 (6.9%) |
| Unknown | 3/43 (6.9%) |
| Gastric cancer | 5/97 (5.1%) |
| Head and neck cancer | 6/122 (4.9%) |
| Lung cancer | 4/119 (3.3%) |
| Colon cancer | 4/123 (3.2%) |
| Gynecologic cancer | 1/86 (1.1%) |
| Breast cancer | 1/89 (1.1%) |
| Urological cancer | 0/38 (0%) |
- Citation: Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Risk factors for de novo hepatitis B during solid cancer treatment. World J Clin Cases 2020; 8(24): 6264-6273
- URL: https://www.wjgnet.com/2307-8960/full/v8/i24/6264.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i24.6264